Ferronova announces preliminary results of MAGMAP, a 62-patient gastric and oesophageal cancer trial investigating lymph node mapping
KYOTO, Japan, Sept. 16, 2026 /PRNewswire/ -- Australian medical technology company Ferronova has announced preliminary findings from the MAGMAP multi-centre trial involving 62 gastric and oesophageal patients evaluating the safety and feasibility of a new nanoparticle-based platform to...
Read the full story on PR Newswire → Opens the original article on www.prnewswire.comSummary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.